Inova Health System

UNLABELLED: Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide. We estimated the global prevalence, incidence, progression, and outcomes of NAFLD and nonalcoholic steatohepatitis (NASH). PubMed/MEDLINE were searched from 1989 to 2015 for terms involving epidemiology and progression of NAFLD. Exclusions included selected groups (studies that exclusively enrolled morbidly obese or diabetics or pediatric) and no data on alcohol consumption or other liver diseases. Incidence of hepatocellular carcinoma (HCC), cirrhosis, overall mortality, and liver-related mortality were determined. NASH required histological diagnosis. All studies were reviewed by three independent investigators. Analysis was stratified by region, diagnostic technique, biopsy indication, and study population. We used random-effects models to provide point estimates (95% confidence interval [CI]) of prevalence, incidence, mortality and incidence rate ratios, and metaregression with subgroup analysis to account for heterogeneity. Of 729 studies, 86 were included with a sample size of 8,515,431 from 22 countries. Global prevalence of NAFLD is 25.24% (95% CI: 22.10-28.65) with highest prevalence in the Middle East and South America and lowest in Africa. Metabolic comorbidities associated with NAFLD included obesity (51.34%; 95% CI: 41.38-61.20), type 2 diabetes (22.51%; 95% CI: 17.92-27.89), hyperlipidemia (69.16%; 95% CI: 49.91-83.46%), hypertension (39.34%; 95% CI: 33.15-45.88), and metabolic syndrome (42.54%; 95% CI: 30.06-56.05). Fibrosis progression proportion, and mean annual rate of progression in NASH were 40.76% (95% CI: 34.69-47.13) and 0.09 (95% CI: 0.06-0.12). HCC incidence among NAFLD patients was 0.44 per 1,000 person-years (range, 0.29-0.66). Liver-specific mortality and overall mortality among NAFLD and NASH were 0.77 per 1,000 (range, 0.33-1.77) and 11.77 per 1,000 person-years (range, 7.10-19.53) and 15.44 per 1,000 (range, 11.72-20.34) and 25.56 per 1,000 person-years (range, 6.29-103.80). Incidence risk ratios for liver-specific and overall mortality for NAFLD were 1.94 (range, 1.28-2.92) and 1.05 (range, 0.70-1.56). CONCLUSIONS: As the global epidemic of obesity fuels metabolic conditions, the clinical and economic burden of NAFLD will become enormous. (Hepatology 2016;64:73-84).

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease, and its worldwide prevalence continues to increase with the growing obesity epidemic. This study assesses the epidemiology of NAFLD in adults based on clinical literature published over the past 30 years. AIM: To review epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults based on clinical literature published over the past 30 years. METHODS: An in-depth search of PubMed (1980-2010) was based on five search terms: 'non-alcoholic fatty liver disease' OR 'non-alcoholic steatohepatitis' OR 'fatty liver' OR 'steatosis' AND 'incidence' [MeSH Terms] OR 'prevalence' [MeSH Terms] OR 'natural history'. Studies of paediatric cohorts were excluded. Articles were categorised by topic and summarised, noting generalisations concerning their content. RESULTS: Four study categories included NAFLD incidence, prevalence, risk factors and natural history. Studies related to NAFLD prevalence and incidence indicate that the diagnosis is heterogeneous and relies on a variety of assessment tools, including liver biopsy, radiological tests such as ultrasonography, and blood testing such as liver enzymes. The prevalence of NAFLD is highest in populations with pre-existing metabolic conditions such as obesity and type II diabetes. Many studies investigating the natural history of NAFLD verify the progression from NASH to advanced fibrosis and hepatocellular carcinoma. CONCLUSIONS: Non-alcoholic fatty liver disease is the most common cause of elevated liver enzymes. Within the NAFLD spectrum, only NASH progresses to cirrhosis and hepatocellular carcinoma. With the growing epidemic of obesity, the prevalence and impact of NAFLD continues to increase, making NASH potentially the most common cause of advanced liver disease in coming decades.

BACKGROUND AND AIMS: NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach. APPROACH AND RESULTS: PubMed and Ovid MEDLINE were searched for NAFLD population-based studies from 1990 to 2019 survey year (last published 2022) per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Meta-analysis was conducted using random-effects models. Bias risk assessment was per Joanna Briggs Institute. Of 2585 studies reviewed, 92 studies (N=9,361,716) met eligibility criteria. Across the study period (1990-2019), meta-analytic pooling of NAFLD prevalence estimates and ultrasound-defined NAFLD yielded an overall global prevalence of 30.05% (95% CI: 27.88%-32.32%) and 30.69% (28.4-33.09), respectively. Global NAFLD prevalence increased by +50.4% from 25.26% (21.59-29.33) in 1990-2006 to 38.00% (33.71-42.49) in 2016-2019 ( p <0.001); ultrasound-defined NAFLD prevalence increased by +38.7% from 25.16% (19.46-31.87) in 1990-2006 to 34.59% (29.05-40.57) ( p =0.029). The highest NAFLD prevalence was in Latin America 44.37% (30.66%-59.00%), then Middle East and North Africa (MENA) (36.53%, 28.63%-45.22%), South Asia (33.83%, 22.91%-46.79%), South-East Asia (33.07%, 18.99%-51.03%), North America (31.20%, 25.86%-37.08%), East Asia (29.71%, 25.96%-33.76%), Asia Pacific 28.02% (24.69%-31.60%), Western Europe 25.10% (20.55%-30.28%). Among the NAFLD cohort diagnosed without a liver biopsy, pooled mortality rate per 1000 PY was 12.60 (6.68-23.67) for all-cause mortality; 4.20 (1.34-7.05) for cardiac-specific mortality; 2.83 (0.78-4.88) for extrahepatic cancer-specific mortality; and 0.92 (0.00-2.21) for liver-specific mortality. CONCLUSIONS: NAFLD global prevalence is 30% and increasing which requires urgent and comprehensive strategies to raise awareness and address all aspects of NAFLD on local, regional, and global levels.

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favor of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panelists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms "nonalcoholic" and "fatty" were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease. There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction-associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction-associated steatotic liver disease, who consume greater amounts of alcohol per week (140-350 g/wk and 210-420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and nonstigmatising, and can improve awareness and patient identification.

The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient advocates were in favour of a change in nomenclature and/or definition. A modified Delphi process was led by three large pan-national liver associations. The consensus was defined a priori as a supermajority (67%) vote. An independent committee of experts external to the nomenclature process made the final recommendation on the acronym and its diagnostic criteria. A total of 236 panellists from 56 countries participated in 4 online surveys and 2 hybrid meetings. Response rates across the 4 survey rounds were 87%, 83%, 83%, and 78%, respectively. Seventy-four percent of respondents felt that the current nomenclature was sufficiently flawed to consider a name change. The terms "nonalcoholic" and "fatty" were felt to be stigmatising by 61% and 66% of respondents, respectively. Steatotic liver disease was chosen as an overarching term to encompass the various aetiologies of steatosis. The term steatohepatitis was felt to be an important pathophysiological concept that should be retained. The name chosen to replace NAFLD was metabolic dysfunction-associated steatotic liver disease (MASLD). There was consensus to change the definition to include the presence of at least 1 of 5 cardiometabolic risk factors. Those with no metabolic parameters and no known cause were deemed to have cryptogenic steatotic liver disease. A new category, outside pure metabolic dysfunction-associated steatotic liver disease, termed metabolic and alcohol related/associated liver disease (MetALD), was selected to describe those with metabolic dysfunction-associated steatotic liver disease, who consume greater amounts of alcohol per week (140-350 g/wk and 210-420 g/wk for females and males, respectively). The new nomenclature and diagnostic criteria are widely supported and non-stigmatising, and can improve awareness and patient identification.

Over the past 2 decades, nonalcoholic fatty liver disease (NAFLD) has grown from a relatively unknown disease to the most common cause of chronic liver disease in the world. In fact, 25% of the world's population is currently thought to have NAFLD. Nonalcoholic steatohepatitis (NASH) is the subtype of NAFLD that can progress to cirrhosis, hepatocellular carcinoma (HCC), and death. NAFLD and NASH are not only found in adults-there is also a high prevalence of these diseases in children and adolescents. Because of the close association of NAFLD with type 2 diabetes (T2DM) and obesity, the latest models predict that the prevalence of NAFLD and NASH will increase, causing a tremendous clinical and economic burden and poor patient-reported outcomes. Nonetheless, there is no accurate noninvasive method to detect NASH, and treatment of this disease is limited to lifestyle modifications. To examine the state of NAFLD among different regions and understand the global trajectory of this disease, an international group of experts came together during the 2017 American Association for the Study of Liver Diseases Global NAFLD Forum. We provide a summary of this forum and an assessment of the current state of NAFLD and NASH worldwide.

BACKGROUND: Interferon alfa is the only effective treatment for patients with chronic hepatitis C. Forty percent of patients have an initial response to this therapy, but most subsequently relapse. We compared the effect of interferon alone with that of interferon plus oral ribavirin for relapses of chronic hepatitis C. METHODS: We studied 345 patients with chronic hepatitis C who relapsed after interferon treatment. A total of 173 patients were randomly assigned to receive standard-dose recombinant interferon alfa-2b concurrently with ribavirin (1000 to 1200 mg orally per day, depending on body weight) for six months, and 172 patients were assigned to receive interferon and placebo. RESULTS: At the completion of treatment, serum levels of hepatitis C virus (HCV) RNA were undetectable in 141 of the 173 patients who were treated with interferon and ribavirin and in 80 of the 172 patients who were treated with interferon alone (82 percent vs. 47 percent, P<0.001). Serum HCV RNA levels remained undetectable 24 weeks after the end of treatment in 84 patients (49 percent) in the combination-therapy group, but in only 8 patients (5 percent) in the interferon group (P<0.001). Sustained normalization of serum alanine aminotransferase concentrations and histologic improvement were highly correlated with virologic response. Base-line serum HCV RNA levels of 2 x 10(6) copies per milliliter or less were associated with higher rates of response in both treatment groups. Viral genotypes other than type 1 were associated with sustained responses only in the combination-therapy group. Combined therapy caused a predictable fall in hemoglobin concentrations but otherwise had a safety profile similar to that of interferon alone. CONCLUSIONS: In patients with chronic hepatitis C who relapse after treatment with interferon, therapy with interferon and oral ribavirin results in higher rates of sustained virologic, biochemical, and histologic response than treatment with interferon alone.

Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease. There is uncertainty around the economic burden of NAFLD. We constructed a steady-state prevalence model to quantify this burden in the United States and Europe. Five models were constructed to estimate the burden of NAFLD in the United States and four European countries. Models were built using a series of interlinked Markov chains, each representing age increments of the NAFLD and the general populations. Incidence and remission rates were calculated by calibrating against real-world prevalence rates. The data were validated using a computerized disease model called DisMod II. NAFLD patients transitioned between nine health states (nonalcoholic fatty liver, nonalcoholic steatohepatitis [NASH], NASH-fibrosis, NASH-compensated cirrhosis, NASH-decompensated cirrhosis, hepatocellular carcinoma, liver transplantation, post-liver transplant, and death). Transition probabilities were sourced from the literature and calibrated against real-world data. Utilities were obtained from NAFLD patients using the Short Form-6D. Costs were sourced from the literature and local fee schedules. In the United States, over 64 million people are projected to have NAFLD, with annual direct medical costs of about $103 billion ($1,613 per patient). In the Europe-4 countries (Germany, France, Italy, and United Kingdom), there are ∼52 million people with NAFLD with an annual cost of about €35 billion (from €354 to €1,163 per patient). Costs are highest in patients aged 45-65. The burden is significantly higher when societal costs are included. CONCLUSION: The analysis quantifies the enormity of the clinical and economic burdens of NAFLD, which will likely increase as the incidence of NAFLD continues to rise. (Hepatology 2016;64:1577-1586).

UNLABELLED: Hepatocellular carcinoma (HCC) is increasingly reported in patients with nonalcoholic fatty liver disease (NAFLD). Our aim was to assess the prevalence and mortality of patients with NAFLD-HCC. We examined Surveillance, Epidemiology and End Results (SEER) registries (2004-2009) with Medicare-linkage files for HCC, which was identified by the International Classification of Diseases for Oncology, third edition codes using topography and morphology codes 8170-8175. Medicare-linked data was used to identify NAFLD, hepatitis C virus (HCV), hepatitis B virus (HBV), alcoholic liver disease (ALD), and other liver disease using International Classification of Diseases, Ninth Revision, Clinical Modification codes. NAFLD was also defined by clinical diagnosis (cryptogenic cirrhosis, obese-diabetics with cryptogenic liver disease). A logistic regression model was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for risk of HCC. In addition, adjusted hazard ratios for 1-year mortality were estimated by Cox's proportional hazard regression. A total of 4,929 HCC cases and 14,937 controls without HCC were included. Of the HCC cases, 54.9% were related to HCV, 16.4% to ALD, 14.1% to NAFLD, and 9.5% to HBV. Across the 6-year period (2004 to 2009), the number of NAFLD-HCC showed a 9% annual increase. NAFLD-HCC were older, had shorter survival time, more heart disease, and were more likely to die from their primary liver cancer (all P < 0.0001). Of those who received a transplant after HCC (n = 488), only 5% were related to NAFLD-HCC. In multivariate analysis, NAFLD increased the risk of 1-year mortality (OR, 1.21; 95% CI: 1.01-1.45). Additionally, older age, lower income, unstaged HCC increased risk of 1-year mortality while receiving a liver transplant (LT), and having localized tumor stage were protective (all P < 0.05). CONCLUSIONS: NAFLD is becoming a major cause of HCC in the United States. NAFLD HCC is associated with shorter survival time, more advanced tumor stage, and lower possibility of receiving a LT.

BACKGROUND AND AIMS: Chronic hepatitis B virus (HBV), hepatitis C virus (HCV), nonalcoholic fatty liver disease (NAFLD), and alcohol-associated liver disease (ALD) are main causes of chronic liver disease. We assessed the global incidence, mortality, and disability-adjusted life-years (DALYs) related to chronic liver disease (primary liver cancer [LC] and cirrhosis). APPROACH AND RESULTS: We obtained data from the 2017 Global Burden of Disease study. In 2017, there were 2.14 million liver-related deaths (2.06-2.30 million), representing an 11.4% increase since 2012 (16.0% increase in LC deaths; 8.7% increase in cirrhosis deaths). LC and cirrhosis accounted for 38.3% and 61.7%, respectively, of liver deaths (LC and cirrhosis deaths were related to HBV [39% and 29%], HCV [29% and 26%], ALD [16% and 25%], and NAFLD [8% and 9%]). Between 2012 and 2017, age-standardized incidence rate, age-standardized death rate (ASDR), and age-standardized DALY rate increased for LC from 11.1 to 11.8, 10.1 to 10.2, and 250.4 to 253.6 per 100,000, respectively. Although age-standardized incidence rate for cirrhosis increased from 66.0 to 66.3, ASDR and age-standardized DALY rate decreased from 17.1 to 16.5 and 532.9 to 510.7, respectively. The largest increase in ASDR for LC occurred in Eastern Europe (annual percent change [APC] = 2.18% [0.89%-3.49%]), whereas the largest decrease occurred in high-income Asia Pacific (APC = -2.88% [-3.58 to -2.18%]). ASDR for LC-NAFLD and ALD increased annually by 1.42% (1.00%-1.83%) and 0.53% (0.08-0.89), respectively, whereas there were no increases for HBV (P = 0.224) and HCV (P = 0.054). ASDR for cirrhosis-NAFLD increased (APC = 0.29% [0.01%-0.59%]) but decreased for ALD (APC = -0.44% [-0.78% to -0.40%]), HCV (APC = -0.50% [-0.81% to -0.18%]), and HBV (APC = -1.43% [-1.71% to -0.40%]). CONCLUSIONS: From 2012 to 2017, the global burden of LC and cirrhosis has increased. Viral hepatitis remains the most common cause of liver deaths, and NAFLD is the most rapidly growing contributor to liver mortality and morbidity.

Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics - from epidemiology, awareness, care and treatment to public health policies and leadership - that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD.

UNLABELLED: Since the initial description of nonalcoholic steatohepatitis (NASH), several sets of pathologic criteria for its diagnosis have been proposed. However, their interprotocol agreement and ability to predict long-term liver-related mortality (LRM) have not been demonstrated. In this study, we examined patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) for whom liver biopsy slides and clinical and mortality data were available. Liver biopsy samples were evaluated for a number of pathologic features and were classified according to the presence or absence of NASH by (1) the original criteria for NAFLD subtypes, (2) the nonalcoholic fatty liver disease activity score (NAS), (3) the Brunt criteria, and (4) the current study's criteria. All NASH diagnostic criteria and individual pathologic features were tested for agreement and for their independent associations with LRM, which were determined with a Cox proportional hazards model. Two hundred fifty-seven NAFLD patients with complete data were included. The diagnoses of NASH by the original NAFLD subtypes and by the current study's definition of NASH were in almost perfect agreement (κ = 0.896). However, their agreement was moderate with NAS (κ = 0.470 and κ = 0.511, respectively) and only fair to moderate with the Brunt criteria (κ = 0.365 and κ = 0.441, respectively). Furthermore, the agreement of the Brunt criteria with NAS was relatively poor (κ = 0.178). During the follow-up (median = 146 months), 31% of the patients died (9% were LRM). After we controlled for confounders, a diagnosis of NASH by the original criteria for NAFLD subtypes [adjusted hazard ratio = 9.94 (95% confidence interval = 1.28-77.08)] demonstrated the best independent association with LRM. Among the individual pathologic features, advanced fibrosis showed the best independent association with LRM [adjusted hazard ratio = 5.68 (95% confidence interval = 1.50-21.45)]. CONCLUSION: The original criteria for NAFLD subtypes and the current study's criteria for NASH were in almost perfect agreement, but their level of agreement with the NAS and Brunt criteria was lower. A diagnosis of NASH by the original criteria for NAFLD subtypes demonstrated the best predictability for LRM in NAFLD patients.

As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does the prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD). Currently, 38% of all adults and 7-14% of children and adolescents have MASLD. By 2040, the MASLD prevalence rate for adults is projected to increase to more than 55%. Although MASLD does not always develop into progressive liver disease, it has become the top indication for liver transplant in the United States for women and those with hepatocellular carcinoma (HCC). Nonetheless, the most common cause of mortality among patients with MASLD remains cardiovascular disease. In addition to liver outcomes (cirrhosis and HCC), MASLD is associated with an increased risk of developing de novo T2D, chronic kidney disease, sarcopenia, and extrahepatic cancers. Furthermore, MASLD is associated with decreased health-related quality of life, decreased work productivity, fatigue, increased healthcare resource utilization, and a substantial economic burden. Similar to other metabolic diseases, lifestyle interventions such as a heathy diet and increased physical activity remain the cornerstone of managing these patients. Although several obesity and T2D drugs are available to treat co-morbid disease, resmetirom is the only MASH-targeted medication for patients with stage 2-3 fibrosis that has approved by the Food and Drug Administration for use in the United States. This review discusses MASLD epidemiology and its related risk factors and outcomes and demonstrates that without further global initiatives, MASLD incidence could continue to increase.

The presence of hepatic steatosis in individuals without a known cause of chronic liver disease, including excessive alcohol consumption, is the hallmark of nonalcoholic fatty liver disease (NAFLD). Although NAFLD is usually associated with obesity, nonobese patients can also present with NAFLD ("lean NAFLD"). Our objective was to determine factors independently associated with lean NAFLD in the United States population. For this purpose, we used data from National Health and Nutrition Examination Survey III (NHANES III) conducted between 1988 and 1994 with available hepatic ultrasound, clinico-demographic, and laboratory data. NAFLD was defined as the presence of moderate-severe hepatic steatosis (by ultrasound), the absence of excessive alcohol use (>20 g/d in men and 10 g/d in women), hepatitis B surface antigen(-), and hepatitis C antibody(-). Nonalcoholic steatohepatitis (NASH) was defined as having moderate-severe steatosis and elevated aminotransferases in the presence of type 2 diabetes or insulin resistance (IR). Logistic regression was used to identify independent predictors of lean NAFLD. As a result, of the 11,613 participants included in the study, 2185 (18.77% ± 0.76%) had NAFLD; of these, 307 (11.78% ± 1.03%) had NASH. Multivariate analysis showed that lean NAFLD was independently associated with younger age, female sex, and a decreased likelihood of having IR and hypercholesterolemia (p values < 0.05). Additionally, multivariate analysis showed that NASH was independently associated with being Hispanic, having a younger age, and having components of metabolic syndrome such as hypertension (p values < 0.05). Therefore, we conclude that lean individuals with NAFLD have a different clinical profile than overweight-obese individuals with NAFLD. Furthermore, patients with NASH are commonly Hispanic and have components of metabolic syndrome.

OBJECTIVE: Given significant advances in treatment of viral hepatitis and the growing epidemic of obesity, the burden of the different types of liver diseases in the USA may be changing. Our aim was to assess the shift in the prevalence of different liver disease aetiologies in the USA over the past three decades. DESIGN: National Health and Nutrition Examination Surveys (NHANES; cross-sectional 1988-1994 and 1999-2016) were used. RESULTS: A total of 58 731 adults from NHANES (1988-2016) were included. Over the study period, the prevalence of chronic hepatitis B and alcoholic liver disease remained stable: 0.3%-0.4% and 0.8%-1.0%, respectively (p>0.05). The prevalence of chronic hepatitis C decreased nearly twofold: 1.6% in 1988-1994 to 0.9% in 2013-2016 (p=0.03). In contrast, the prevalence of non-alcoholic fatty liver disease (NAFLD; by US-Fatty Liver Index) increased from 20.0% (1988-1994) to 28.3% (1999-2004) to 33.2% (2009-2012) and 31.9% (2013-2016) (p<0.0001). Furthermore, steady increases were observed in the rates of obesity (22.2% in 1988-1994 to 31.0% in 1999-2004 to 38.9% in 2013-2016), type 2 diabetes mellitus (T2DM) (from 7.2% to 8.2% to 13.5% same years), insulin resistance and hypertension (all p<0.0001). Yearly trend analyses showed that the only LD with consistently increasing prevalence was NAFLD (trend p=0.01). Multivariable regression analysis showed that obesity (OR 10.4; 95% CI 9.5 to 11.3) and T2DM (OR 3.7; 95% CI 3.2 to 4.2) were the major independent predictors of NAFLD. CONCLUSIONS: Over the past 30 years in the USA, NAFLD is the only liver disease with growing prevalence, synchronous with the increasing rates of obesity and T2DM.

Sarcopenia is the loss of muscle strength, mass, and function, which is often exacerbated by chronic comorbidities including cardiovascular diseases, chronic kidney disease, and cancer. Sarcopenia is associated with faster progression of cardiovascular diseases and higher risk of mortality, falls, and reduced quality of life, particularly among older adults. Although the pathophysiologic mechanisms are complex, the broad underlying cause of sarcopenia includes an imbalance between anabolic and catabolic muscle homeostasis with or without neuronal degeneration. The intrinsic molecular mechanisms of aging, chronic illness, malnutrition, and immobility are associated with the development of sarcopenia. Screening and testing for sarcopenia may be particularly important among those with chronic disease states. Early recognition of sarcopenia is important because it can provide an opportunity for interventions to reverse or delay the progression of muscle disorder, which may ultimately impact cardiovascular outcomes. Relying on body mass index is not useful for screening because many patients will have sarcopenic obesity, a particularly important phenotype among older cardiac patients. In this review, we aimed to: (1) provide a definition of sarcopenia within the context of muscle wasting disorders; (2) summarize the associations between sarcopenia and different cardiovascular diseases; (3) highlight an approach for a diagnostic evaluation; (4) discuss management strategies for sarcopenia; and (5) outline key gaps in knowledge with implications for the future of the field.

Chronic liver disease (CLD) and its associated complications (cirrhosis and liver cancer) cause significant mortality, morbidity, and economic burden. Published data from the World Health Organization and/or the Global Burden of Disease show that the burden of CLD is large and increasing, primarily owing to the increasing burden of nonalcoholic fatty liver disease and alcohol-related liver disease (ALD). Middle Eastern, Northern African, and Asian regions of the globe are most affected by hepatitis B and hepatitis C virus. Furthermore, Middle Eastern and North African regions also are affected by nonalcoholic fatty liver disease, and Eastern European, West African, and Central Asian regions are affected by ALD. In this context, the rate of increase for cirrhosis is highest in the Middle East, as well as in middle high and high sociodemographic index (SDI) regions. On the other hand, the highest SDI countries are experiencing increasing rates of hepatocellular carcinoma (HCC). Assessing HCC burden based on country and etiology shows that China, Korea, India, Japan, and Thailand have the highest hepatitis B virus–related HCC cases, while China, Japan, and the United States have the highest hepatitis C virus–related HCC cases. Additionally, the United States has the highest ALD-related HCC cases, while India, the United States, and Thailand have the highest nonalcoholic steatohepatitis–related HCC cases. Although the burden of CLD is increasing globally, regions of the world are impacted differently as a result of a number of sociodemographic factors. Chronic liver disease (CLD) and its associated complications (cirrhosis and liver cancer) cause significant mortality, morbidity, and economic burden. Published data from the World Health Organization and/or the Global Burden of Disease show that the burden of CLD is large and increasing, primarily owing to the increasing burden of nonalcoholic fatty liver disease and alcohol-related liver disease (ALD). Middle Eastern, Northern African, and Asian regions of the globe are most affected by hepatitis B and hepatitis C virus. Furthermore, Middle Eastern and North African regions also are affected by nonalcoholic fatty liver disease, and Eastern European, West African, and Central Asian regions are affected by ALD. In this context, the rate of increase for cirrhosis is highest in the Middle East, as well as in middle high and high sociodemographic index (SDI) regions. On the other hand, the highest SDI countries are experiencing increasing rates of hepatocellular carcinoma (HCC). Assessing HCC burden based on country and etiology shows that China, Korea, India, Japan, and Thailand have the highest hepatitis B virus–related HCC cases, while China, Japan, and the United States have the highest hepatitis C virus–related HCC cases. Additionally, the United States has the highest ALD-related HCC cases, while India, the United States, and Thailand have the highest nonalcoholic steatohepatitis–related HCC cases. Although the burden of CLD is increasing globally, regions of the world are impacted differently as a result of a number of sociodemographic factors. Chronic liver disease (CLD) and associated cirrhosis accounts for approximately 1 million deaths per year. In addition to its clinical burden, CLD causes significant morbidity, impairment of health-related quality of life (HRQL), and economic burden.1Asrani S.K. Devarbhavi H. Eaton J. Kamath P.S. Burden of liver diseases in the world.J Hepatol. 2019; 70: 151-171Abstract Full Text Full Text PDF PubMed Scopus (1522) Google Scholar Although there are a number of causes of liver disease, the 4 major drivers of this CLD-related burden include chronic hepatitis C virus (CHC), chronic hepatitis B virus (CHB), alcohol-related liver disease (ALD), and nonalcoholic fatty liver disease (NAFLD). In fact, given the pandemic of obesity, its associated liver disease, NAFLD, is increasing and is predicted to continue to do so.2Paik J.M. Golabi P. Younossi Y. et al.Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD.Hepatology. 2020; 72: 1605-1616Crossref PubMed Scopus (272) Google Scholar, 3Estes C. Anstee Q.M. Arias-Loste M.T. et al.Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.J Hepatol. 2018; 69: 896-904Abstract Full Text Full Text PDF PubMed Scopus (876) Google Scholar, 4Estes C. Razavi H. Loomba R. et al.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology. 2018; 67: 123-133Crossref PubMed Scopus (1108) Google Scholar, 5Estes C. Chan H.L.Y. Chien R.N. et al.Modelling NAFLD disease burden in four Asian regions-2019-2030.Aliment Pharmacol Ther. 2020; 51: 801-811Crossref PubMed Scopus (66) Google Scholar, 6World Health OrganizationEstimated mortality rate from cirrhosis and other chronic liver diseases.https://www.who.int/data/gho/indicator-metadata-registry/imr-details/1179Date accessed: December 13, 2022Google Scholar, 7World Health Statistics.file:///C:/Users/User/Downloads/9789240051140-eng.pdfDate accessed: December 13, 2022Google Scholar, 8Rehm J. Gmel Sr., G.E. Gmel G. et al.The relationship between different dimensions of alcohol use and the burden of disease-an update.Addiction. 2017; 112: 968-1001Crossref PubMed Scopus (593) Google Scholar, 9Rehm J. Imtiaz S. A narrative review of alcohol consumption as a risk factor for global burden of disease.Subst Abuse Treat Prev Policy. 2016; 11: 37Crossref PubMed Scopus (105) Google Scholar, 10Messina J.P. Humphreys I. Flaxman A. et al.Global distribution and prevalence of hepatitis C virus genotypes.Hepatology. 2015; 61: 77-87Crossref PubMed Scopus (1173) Google Scholar, 11Schwarzinger M. Baillot S. Y. et use and the burden of chronic hepatitis C in France, a Hepatol. 2017; 67: Full Text Full Text PDF PubMed Scopus Google Scholar, J. Global burden of alcohol use and alcohol liver 2019; PubMed Scopus Google Scholar, Golabi P. J.M. et al.The global of nonalcoholic fatty liver disease and a review and PubMed Scopus Google Scholar the of CLD is for and global to this review an of the burden and to 4 major causes of CLD from a global the World Health Organization that million have approximately million and approximately deaths Health OrganizationEstimated mortality rate from cirrhosis and other chronic liver diseases.https://www.who.int/data/gho/indicator-metadata-registry/imr-details/1179Date accessed: December 13, 2022Google Health Statistics.file:///C:/Users/User/Downloads/9789240051140-eng.pdfDate accessed: December 13, 2022Google Scholar Furthermore, is that million and are highest burden of is in the Eastern and by the and the Health OrganizationEstimated mortality rate from cirrhosis and other chronic liver diseases.https://www.who.int/data/gho/indicator-metadata-registry/imr-details/1179Date accessed: December 13, 2022Google Health Statistics.file:///C:/Users/User/Downloads/9789240051140-eng.pdfDate accessed: December 13, 2022Google Disease by Global Organization liver B million million most Eastern million most and million most C million million million most Eastern regions of the million million million per million from most and million million most Eastern and fatty liver by the as a million are to have NAFLD per most Middle and North by China, India, and highest rate per burden of mortality and life liver deaths for of liver highest life Eastern West Central of of and prevalence of deaths from liver of liver of is alcohol-related liver Global Burden of World Health from et M. M. 2019; Full Text Full Text PDF PubMed Scopus Google Scholar Global on hepatitis World Health Scholar in hepatitis C virus prevalence and of between and a Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar and and of hepatitis B virus in a Hepatol. 2018; Full Text Full Text PDF PubMed Scopus Google Scholar in a alcohol-related liver Global Burden of World Health from et M. M. 2019; Full Text Full Text PDF PubMed Scopus Google Scholar Global on hepatitis World Health Scholar in hepatitis C virus prevalence and of between and a Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar and and of hepatitis B virus in a Hepatol. 2018; Full Text Full Text PDF PubMed Scopus Google Scholar In addition to the the disease burden data for CLD from the global burden of disease for Health and an global the of is for the and for Health and accessed: December 13, 2022Google Scholar of and is to data to and that the global in for Health and accessed: December 13, 2022Google Scholar of the that use to for of accessed: December 13, 2022Google Scholar that are to the global burden of for Health and accessed: December 13, 2022Google accessed: December 13, 2022Google Scholar global impact of data has in a by the global M. M. 2019; Full Text Full Text PDF PubMed Scopus Google Scholar that the prevalence of hepatitis C virus in million cases, for million and for million cases. a million deaths to for of the rate for per M. M. 2019; Full Text Full Text PDF PubMed Scopus Google Scholar the of for Y. et of and for hepatitis B virus and hepatitis C virus an by and 2020; Full Text Full Text PDF PubMed Scopus Google Scholar, Y. et for hepatitis in and 2019; Full Text Full Text PDF PubMed Scopus Google Scholar, M.T. S. M. et al.Global of for chronic hepatitis C virus a review and PubMed Scopus Google Scholar, A. et for the of chronic hepatitis C virus a review and 2020; Full Text Full Text PDF PubMed Scopus Google Scholar, R. et for the of hepatitis C virus a review of Hepatol. 2019; Full Text Full Text PDF PubMed Scopus Google Scholar the cause of the cause for of life the cause for of life and the cause for A large of to are for by the of Y. et of and for hepatitis B virus and hepatitis C virus an by and 2020; Full Text Full Text PDF PubMed Scopus Google Scholar In other of Asian and African regions the highest prevalence of for the countries of the Central African and the burden of for to countries the highest burden for and to are given the that data that of have and of S. C. et al.Global of of hepatitis B and hepatitis Hepatol. Full Text Full Text PDF PubMed Google S. et hepatitis B and C in the and from and global PubMed Scopus Google Scholar In countries are on to hepatitis by and the countries the highest burden of the Global on hepatitis World Health S. et of global and data Scholar In addition to and the global to an on the of in hepatitis C virus prevalence and of between and a Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar have that there million the of to Eastern and Central have the highest prevalence of while the number of of is in and is that an of million the of of hepatocellular and are to increase by to increase from that of have and have significant in the in hepatitis C virus prevalence and of between and a Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar that million in million and an deaths owing to cirrhosis and hepatocellular Health OrganizationEstimated mortality rate from cirrhosis and other chronic liver diseases.https://www.who.int/data/gho/indicator-metadata-registry/imr-details/1179Date accessed: December 13, 2022Google Health Statistics.file:///C:/Users/User/Downloads/9789240051140-eng.pdfDate accessed: December 13, 2022Google Scholar burden of is highest in the by as well as the Eastern and the Health OrganizationEstimated mortality rate from cirrhosis and other chronic liver diseases.https://www.who.int/data/gho/indicator-metadata-registry/imr-details/1179Date accessed: December 13, 2022Google Health Statistics.file:///C:/Users/User/Downloads/9789240051140-eng.pdfDate accessed: December 13, 2022Google Scholar the global prevalence to million of hepatitis B virus B and burden of hepatitis a for the Global Burden of Disease Hepatol. Full Text Full Text PDF PubMed Google Scholar also that in there B and burden of hepatitis a for the Global Burden of Disease Hepatol. Full Text Full Text PDF PubMed Google J.M. Younossi Y. et in the global burden of hepatitis B Full Text Full Text PDF PubMed Scopus Google Scholar that there has a in the prevalence of between and most J.M. Younossi Y. et in the global burden of hepatitis B Full Text Full Text PDF PubMed Scopus Google Scholar this in rates are to increase in owing to the of the as well as that is to the prevalence rates a in global hepatitis B is of the world PubMed Google Scholar, et of hepatitis B in countries Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar, et B impact and the for in PubMed Scopus Google Scholar to the burden of for the countries and B also have a on and of hepatitis B virus in a Hepatol. 2018; Full Text Full Text PDF PubMed Scopus Google Scholar that the global prevalence of hepatitis B in to approximately million cases. of have and of have In of are in and from and the global hepatitis B is of the world PubMed Google Scholar, et of hepatitis B in countries Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar, et B impact and the for in PubMed Scopus Google Scholar to rates of and in regions. in of of the hepatitis B of et B impact and the for in PubMed Scopus Google Scholar data for that to on the regions the highest burden of to and this cause of global hepatitis B is of the world PubMed Google Scholar, et of hepatitis B in countries Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar, et B impact and the for in PubMed Scopus Google Scholar On a is that countries the to hepatitis B prevalence in to by On the other hand, the highest prevalence are to the S. C. et al.Global of of hepatitis B and hepatitis Hepatol. Full Text Full Text PDF PubMed Google Scholar In addition to is a major cause of CLD Health OrganizationEstimated mortality rate from cirrhosis and other chronic liver diseases.https://www.who.int/data/gho/indicator-metadata-registry/imr-details/1179Date accessed: December 13, 2022Google Health Statistics.file:///C:/Users/User/Downloads/9789240051140-eng.pdfDate accessed: December 13, 2022Google Scholar the of on the of alcohol is J. Gmel Sr., G.E. Gmel G. et al.The relationship between different dimensions of alcohol use and the burden of disease-an update.Addiction. 2017; 112: 968-1001Crossref PubMed Scopus (593) Google Scholar In given that alcohol consumption is associated for burden are to J. Gmel Sr., G.E. Gmel G. et al.The relationship between different dimensions of alcohol use and the burden of disease-an update.Addiction. 2017; 112: 968-1001Crossref PubMed Scopus (593) Google J. Imtiaz S. A narrative review of alcohol consumption as a risk factor for global burden of disease.Subst Abuse Treat Prev Policy. 2016; 11: 37Crossref PubMed Scopus (105) Google Scholar Furthermore, other liver in is to the for liver J.P. Humphreys I. Flaxman A. et al.Global distribution and prevalence of hepatitis C virus genotypes.Hepatology. 2015; 61: 77-87Crossref PubMed Scopus (1173) Google M. Baillot S. Y. et use and the burden of chronic hepatitis C in France, a Hepatol. 2017; 67: Full Text Full Text PDF PubMed Scopus Google Scholar data from the Global on and Health have the burden of J. Global burden of alcohol use and alcohol liver 2019; PubMed Scopus Google Scholar that alcohol consumption of the deaths to CLD in and of liver disease to deaths Furthermore, of of CLD to ALD. is that the highest rates to in Eastern European, West African, and Central Asian J. Global burden of alcohol use and alcohol liver 2019; PubMed Scopus Google Scholar Although the for alcohol use and associated prevalence of ALD. is owing to a of and that the to and have that alcohol is for of deaths from liver disease and of liver deaths use and burden for countries and a for the Global Burden of Disease 2018; Full Text Full Text PDF PubMed Scopus Google Scholar has impacted the burden of to impact most regions of the In and the countries affected NAFLD is as the most cause of CLD in different regions of the J.M. Golabi P. Younossi Y. et al.Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD.Hepatology. 2020; 72: 1605-1616Crossref PubMed Scopus (272) Google Scholar NAFLD is by the as an Health of disease for accessed: Scholar, burden of risk in countries and a for the Global Burden of Disease 2020; Full Text Full Text PDF PubMed Scopus Google Scholar, H. et al.The global burden of disease to high index in countries and an of the Global Burden of Disease 2020; Scopus Google Scholar the global prevalence for NAFLD have and most that the global prevalence for NAFLD is the data from to the NAFLD prevalence to as high as Golabi P. J.M. et al.The global of nonalcoholic fatty liver disease and a review and PubMed Scopus Google Scholar for the burden of NAFLD are the for liver complications (cirrhosis and liver cancer) to NAFLD and data for the prevalence of accessed: December 13, 2022Google Scholar the use of the data have that the NAFLD prevalence for has from in to in an of burden of risk in countries and a for the Global Burden of Disease 2020; Full Text Full Text PDF PubMed Scopus Google Scholar the global prevalence of NAFLD increasing by approximately J.M. Younossi Y. et al.The burden of fatty liver disease is growing in of the world from to Hepatol. Full Text PDF Google Scholar In in for of the global and of the global NAFLD liver rates by China, India, and highest NAFLD prevalence rate in the Middle and North In addition to the increasing NAFLD liver rates also have by the highest NAFLD liver deaths in Central deaths per J.M. Younossi Y. et al.The burden of fatty liver disease is growing in of the world from to Hepatol. Full Text PDF Google Scholar In a NAFLD to have the highest prevalence the liver diseases and the Middle the most affected of the countries the burden of NAFLD United and accessed: December 13, 2022Google Scholar NAFLD data the global of disease burden from North and to Middle Eastern and North African, and North has a high NAFLD prevalence rate of an of from to In rates to NAFLD also in North an of from to an of to J.M. Younossi Y. et al.The burden of fatty liver disease is growing in of the world from to Hepatol. Full Text PDF Google Scholar Eastern the highest NAFLD prevalence rate in a rate increase of for and for Central the highest NAFLD prevalence rate in a a NAFLD prevalence rate of in in to Eastern and Central rate of increase to and In addition to the high prevalence of NAFLD, Eastern also the highest liver rate from NAFLD for to the highest liver rate from NAFLD in a rate of in liver rate to from to to the from to that the liver rate from NAFLD increasing Central the liver rate from NAFLD in to and to J.M. Younossi Y. et al.The burden of fatty liver disease is growing in of the world from to Hepatol. Full Text PDF Google Scholar that from to the global deaths from liver to NAFLD liver deaths to other liver diseases and J.M. Younossi Y. et al.The burden of fatty liver disease is growing in of the world from to Hepatol. Full Text PDF Google Scholar also has a for disease risk that to in is in risk and in are to for 1 risk include alcohol and to and and high high and burden of risk in countries and a for the Global Burden of Disease 2020; Full Text Full Text PDF PubMed Scopus Google Scholar In the review of risk the in risk to high and high index of are associated are to NAFLD and nonalcoholic in the burden of risk to that for and to and burden of risk in countries and a for the Global Burden of Disease 2020; Full Text Full Text PDF PubMed Scopus Google H. et al.The global burden of disease to high index in countries and an of the Global Burden of Disease 2020; Scopus Google Scholar In fact, the global deaths and to high are to have for and H. et al.The global burden of disease to high index in countries and an of the Global Burden of Disease 2020; Scopus Google Scholar Although the rate of deaths has by for and by for H. et al.The global burden of disease to high index in countries and an of the Global Burden of Disease 2020; Scopus Google Scholar the of NAFLD, major drivers of in the In the rate of cirrhosis per for a increase and the rate by regions of the an rate of per in per in and per in of chronic liver disease and Hepatol. 2020; Full Text Full Text PDF PubMed Scopus Google Scholar review data that the number of of cirrhosis from to by in the rate per cirrhosis prevalence by the global and the highest number of cases. growing regions the and while the of the United the Furthermore, the highest for and the United the increase by in and the On the other hand, the in cirrhosis M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google of by Chronic Disease B C fatty liver disease and liver increase from to number of and regions are regions are for Eastern and North regions and United United United and increasing and increasing increasing United increasing and increasing in middle high and high in the middle SDI in SDI regions increasing in Eastern and North in SDI the middle and middle high in SDI nonalcoholic from et M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar the accessed: Scholar and the Global Burden of Disease and burden of cirrhosis by cause in countries and a for the Global Burden of Disease Hepatol. 2020; Full Text Full Text PDF PubMed Scopus Google Scholar in a nonalcoholic from et M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar the accessed: Scholar and the Global Burden of Disease and burden of cirrhosis by cause in countries and a for the Global Burden of Disease Hepatol. 2020; Full Text Full Text PDF PubMed Scopus Google Scholar is to that in the etiology of cirrhosis while of and cirrhosis M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar of cirrhosis for and an of and to etiology of liver disease, a for and M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar also prevalence by SDI is a countries other on the of of per and SDI is on a of to 1 an the highest of the United and an the of of the the world 1 of SDI high and SDI has to accessed: Scholar from to the most in cirrhosis in the and high SDI M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar in causes of cirrhosis are prevalence of cirrhosis for by the number of cases, the increase of cirrhosis while the highest in the for cirrhosis to in SDI in the middle SDI regions as well as global M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar cirrhosis prevalence by the number of cases, the United the increase in highest in the increase in In the most in in the in SDI regions increasing for Eastern and North are M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar to ALD-related cirrhosis prevalence by of cirrhosis by alcohol in and SDI regions. Although the highest number of cases, and the highest In the in SDI regions and in regions for and the rate of ALD-related cirrhosis to M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar liver cirrhosis has to the etiology of for of use and burden for countries and a for the Global Burden of Disease 2018; Full Text Full Text PDF PubMed Scopus Google Scholar In fact, the increase to a increase in the number of to In this context, the number of in the United the highest in SDI regions in the middle and middle high M. J. S. et al.The burden of liver cirrhosis and from the global burden of disease PubMed Google Scholar in cirrhosis for of global deaths million Although the number of of deaths the rate from per to per the highest deaths per while the deaths per Eastern and Central increasing deaths owing to alcohol-related liver the country the in and highest in the in deaths by liver disease from to and burden of cirrhosis by cause in countries and a for the Global Burden of Disease Hepatol. 2020; Full Text Full Text PDF PubMed Scopus Google Scholar In addition to hepatocellular carcinoma is of CLD G. J. M. on hepatitis B by the global burden of liver disease to hepatitis B and PubMed Scopus Google Scholar and Burden of Disease J.M. et mortality, of life and life for from to a for the Global Burden of Disease PubMed Scopus Google Scholar, Chan et on Hepatol. Full Text Full Text PDF PubMed Scopus Google Scholar In this context, most of the of liver are to the rate of HCC to an of is the rate of per in a of to Although the rates are continue to have a rate for H. et al.The global burden of disease to high index in countries and an of the Global Burden of Disease 2020; Scopus Google Scholar rate is most owing to the rates of HCC for and and rates for NAFLD and ALD. rate are most a result of the of different global as for of M. M. et in and burden and quality of index for liver by cause from global burden of disease PubMed Scopus Google of by Chronic Disease B C liver cases, in increase and and North number of number of number of number of number of of number of number of number of number of of of of rates in high rates in high rates in high rates in rates in from Global Burden of Disease Burden of Disease J.M. et mortality, of life and life for from to a for the Global Burden of Disease PubMed Scopus Google Scholar et M. M. et in and burden and quality of index for liver by cause from global burden of disease PubMed Scopus Google Scholar et Y. J. J. et al.Global burden of liver by and global by based on global burden of disease 11: PubMed Scopus Google Scholar and et G. J. M. on hepatitis B by the global burden of liver disease to hepatitis B and PubMed Scopus Google Scholar in a from Global Burden of Disease Burden of Disease J.M. et mortality, of life and life for from to a for the Global Burden of Disease PubMed Scopus Google Scholar et M. M. et in and burden and quality of index for liver by cause from global burden of disease PubMed Scopus Google Scholar et Y. J. J. et al.Global burden of liver by and global by based on global burden of disease 11: PubMed Scopus Google Scholar and et G. J. M. on hepatitis B by the global burden of liver disease to hepatitis B and PubMed Scopus Google Scholar In other data the rates of liver for major and Y. J. J. et al.Global burden of liver by and global by based on global burden of disease 11: PubMed Scopus Google Scholar in that the for liver from alcohol owing to owing to owing to and owing to other also between the in liver to and in while and liver a in are by and alcohol have a and Although liver to in globally, high SDI countries an in liver countries the increase and North Eastern and and Central the and prevalence of liver in between and while for the the of on that the global rate of liver in owing to in to and from there is between to M. M. et in and burden and quality of index for liver by cause from global burden of disease PubMed Scopus Google Y. J. J. et al.Global burden of liver by and global by based on global burden of disease 11: PubMed Scopus Google Scholar In on the global liver the most cause of for for of global H. et al.The global burden of disease to high index in countries and an of the Global Burden of Disease 2020; Scopus Google Scholar in the rate between and the number of deaths rates of liver from causes the the most for In this context, and NAFLD deaths are increasing while deaths from to the shows a Burden of Disease J.M. et mortality, of life and life for from to a for the Global Burden of Disease PubMed Scopus Google Scholar is an that the of and quality accessed: 2022Google Scholar In other for CLD include and are and are and most to CLD are the and the the Chronic Disease its of and M. a PubMed Scopus Google Scholar, G. M. et of a disease to quality of life in chronic liver PubMed Google Scholar, M. and of Chronic Disease C in clinical of chronic hepatitis 2016; Full Text Full Text PDF PubMed Google Scholar, M. et quality of life for fatty liver disease and 2017; PubMed Scopus Google Scholar, M. Younossi I. A. of Chronic Disease for nonalcoholic in nonalcoholic Hepatol. 2019; Full Text Full Text PDF PubMed Scopus Google Scholar, M. Younossi I. A. and of a hepatitis health-related PubMed Scopus Google Scholar, M. Younossi I. A. Younossi of in chronic hepatitis C the Chronic Disease C 2018; Full Text Full Text PDF PubMed Scopus Google Scholar is the and while is the of Chronic the and of a and impairment PubMed Google Scholar, A. et al.The of Chronic of 4 of the Scholar, J. et al.The to and

ABBREVIATIONS: ASIA, American Spinal Injury Association MP, Methylprednisolone NASCIS, National Acute Spinal Cord Injury Study SCI, spinal cord injury

BACKGROUND: Several adipocytokines have been implicated in the pathogenesis non-alcoholic fatty liver disease (NAFLD). AIM: To assess adipocytokines in NAFLD patients and controls. METHODS: A total of 95 patients (26 non-alcoholic steatohepatitis (NASH), 19 simple steatosis (SS), 38 obese controls and 12 non-obese controls) were included. Fasting serum insulin, glucose, visfatin, resistin, adiponectin, tumour necrosis factor-alpha (TNF-alpha), interleukin-8 (IL-8) and IL-6 were determined. Univariate and multivariate analyses were used to compare groups and determine associations. RESULTS: Serum TNF-alpha and IL-8 were higher in NAFLD patients when compared with both obese and non-obese controls. Analysis involving all patients revealed a significant correlation between serum TNF-alpha and IL-8 (P < 6.319e-08), and between IL-6 and IL-8 (P < 5.271e-15). Homeostatic model assessment scores negatively correlated with adiponectin in NAFLD (P < 0.0032). Serum visfatin was higher in all three obese groups than in non-obese controls (P < 0.02, P < 0.002 and P < 0.008). Visfatin in NASH patients was lower than SS and obese controls. Although TNF-alpha was associated with NAFLD (P < 0.02), it was interdependent on visfatin. In comparison to SS, four factors were independently associated with NASH: age, alanine aminotransferase, IL-8 and adiponectin (P < 0.05). Multivariate analysis indicated that TNF-alpha was the only independent predictor of fibrosis in NASH (P < 0.0004). CONCLUSION: These findings support a complex interaction between adipocytokines and the pathogenesis of NAFLD.

Nonalcoholic fatty liver disease (NAFLD) is a spectrum comprised of isolated steatosis, nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. The majority of NAFLD subjects do not have NASH and do not carry a significant risk for liver-related adverse outcomes (cirrhosis and mortality). Globally, the prevalence of NAFLD is approximately 25%. In Asia, a gradient of high to low prevalence rates is noted from urban to rural areas. Given the prevalence of NAFLD, the clinical and economic burden of NAFLD and NASH can be substantial. With increasing recognition of NASH as an important liver disease, the diagnosis of NASH still requires a liver biopsy that is suboptimal. Although liver biopsy is the most accurate modality to diagnose and stage the severity of NASH, this method suffers from being invasive, costly, associated with potential complications, and plagued with interobserver variability of individual pathological features. A number of noninvasive modalities to diagnose NASH and stage liver fibrosis are being developed. These modalities include predictive models (NAFLD fibrosis score) and serum biomarkers such as enhanced liver fibrosis (ELF). Other tests are based on radiological techniques, such as transient elastography (TE) or magnetic resonance elastography (MRE), which are used to estimate liver stiffness as a potential surrogate of hepatic fibrosis. Although a dynamic field of research, most of these diagnostic modalities have area under the curve ranging between 0.76 and 0.90%, with MRE having the best predictive performance. In summary, developing safe and easily accessible noninvasive modalities to accurately diagnose and monitor NASH and associated fibrosis is of utmost importance in clinical practice and clinical research. These tests are not only important to risk stratify subjects at the greatest risk for progressive liver disease, but also to serve as appropriate surrogate endpoints for therapeutic clinical trials of NASH. (Hepatology 2018;68:349-360).